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Background:  Apolipoprotein A-II (apoA-II) is the second-most abundant apolipoprotein in human high-density lipoprotein 
and its role in cardio metabolic risk is not entirely clear. It has been suggested to have poor anti-atherogenic or even pro-athero-
genic properties, but there are few studies on the possible role of apoA-II in Asian populations. The aim of this study is to evalu-
ate the role of apoA-II in metabolic syndrome (MetS) compared with apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) 
in Korean adults. 
Methods:  We analyzed data from 244 adults who visited the Center for Health Promotion in Pusan National University Yang-
san Hospital for routine health examinations. 
Results:  The mean apoB level was significantly higher, and the mean apoA-I level was significantly lower, in MetS; however, 
there was no significant difference in apoA-II levels (30.5±4.6 mg/dL vs. 31.2±4.6 mg/dL, P=0.261). ApoA-II levels were more 
positively correlated with apoA-I levels than apoB levels. ApoA-II levels were less negatively correlated with homocysteine and 
high sensitivity C-reactive protein levels than apoA-I levels. The differences in MetS prevalence from the lowest to highest quar-
tile of apoA-II were not significant (9.0%, 5.7%, 4.9%, and 6.6%, P=0.279). The relative risk of the highest quartile of apoA-II 
compared with the lowest quartile also was not significantly different (odds ratio, 0.96; 95% confidence interval, 0.95 to 1.04; 
P=0.956).
Conclusion:  Compared with apoA-I (negative association with MetS) and apoB (positive association with MetS) levels, apoA-II 
levels did not show any association with MetS in this study involving Korean adults. However, apoA-II may have both anti-ath-
erogenic and pro-atherogenic properties. 
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INRTODUCTION
Plasma high density lipoprotein (HDL) is very heterogeneous, 
but apolipoprotein A-I (apoA-I) and apolipoprotein A-II 
(apoA-II) are two main sub-populations of HDL [1]. The anti-
atherogenic properties of apoA-I, the major structural apoli-
poprotein of HDL, are widely known [2-5], but in the case of 
apoA-II, the second most abundant structural apolipoprotein 
associated with HDL [1], the role on these properties is con-
troversial. There have been several studies, showing an inverse 
relationship between cardiovascular disease, including type 2 
diabetes mellitus, and plasma apoA-II levels [6-9]; however, 
other studies have suggested that elevated apoA-II levels may 
be pro-atherogenic [10], or have shown no relationship be-
tween cardiovascular disease and apoA-II levels [11,12].
  Recently, Onat et al. [13] showed that low serum apoA-II 
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concentrations confer risk of metabolic syndrome (MetS) and 
type 2 diabetes mellitus among Turkish adults at 4 years fol-
low-up. There are few studies about the association between 
apoA-II and MetS, a constellation of atherosclerotic cardiovas-
cular disease risk factors [14], and the possible properties of 
apoA-II in cardiovascular risk are even less clear, especially in 
Asian populations. Therefore, we tried to investigate the rela-
tionship of apoA-II with MetS and other inflammatory mark-
ers in Korean adults and the possible roles of apoA-II in com-
parison with other well-known lipid markers, such as apoA-I 
(anti-atherogenic) and apoB (pro-atherogenic).
METHODS
Subjects and measurements
Our study subjects included 244 adults (20 to 70 years of age; 
159 men and 85 women) who visited the Center for Health 
Promotion at Pusan National University Yangsan Hospital for 
routine health examinations between December 2009 and 
April 2010. All subjects had no history of coronary heart dis-
ease (CHD) or cerebro-vascular disease. Subjects who were 
being treated with lipid-modifying agents or on estrogen re-
placement therapy, and those with hyperthyroidism, hypothy-
roidism, liver disease (serum levels of aspartate aminotrans-
ferase [AST] or alanine aminotransferase [ALT] were greater 
than three times the upper limit of the reference range), serum 
triglyceride levels ≥ 400 mg/dL, or abnormal serum creatinine 
levels (male, ≥1.5 mg/dL; female ≥1.3 mg/dL) were excluded. 
Height and weight were measured while subjects wore light 
clothing without shoes. Body mass index (BMI) was calculat-
ed as weight (kg) divided by height (m) squared and was used 
as an estimate of overall adiposity. Waist circumference, an es-
timate of central obesity, was measured with a soft tape on 
standing subjects midway between the lowest rib and the iliac 
crest. Blood pressure was measured on the right arm with sub-
jects in a sitting position after a 5-minute rest. Venous blood 
was sampled after an overnight fast. Fasting glucose was mea-
sured by the glucose oxidase method (Synchron LX-20; Beck-
man Coulter Inc., Fullerton, CA, USA). Standard liver enzyme, 
total cholesterol, HDL cholesterol (HDL-C), and serum tri-
glyceride (TG) concentrations were measured with an autoan-
alyzer using an enzymatic colorimetric method (Hitachi 7600; 
Hitachi Ltd., Tokyo, Japan). Serum levels of apoA-I, apoA-II, 
and apoB were measured by turbidimetric immuno assay us-
ing the automatic immunoassay analyzer Roche E-170 (Roche, 
Basel, Switzerland). The metabolic syndrome criteria used were 
those of the modified, revised NCEP-ATP III (using the WHO 
Western Pacific Region obesity criteria and defining glucose 
levels as ≥100 mg/dL [5.24 mmol/L]) [15,16], which defines 
metabolic syndrome as the presence of at least three of the fol-
lowing five traits: 1) Abdominal obesity: waist circumference 
≥90 cm in men, ≥80 cm in women, 2) Hypertriglyceridemia 
(HyperTG): ≥150 mg/dL, (1.70 mmol/L), 3) Low HDL-C: <40 
mg/dL (1.03 mmol/L) in men and <50 mg/dL (1.29 mmol/L) in 
women, 4) Hypertension: systolic blood pressure ≥130 mm Hg 
or diastolic pressure ≥85 mm Hg or on anti-hypertensive med-
ication, 5) High fasting glucose: ≥100 mg/dL (5.54 mmol/L) 
or under treatment for diabetes. This study was approved by 
the Ethical Committee of Pusan National University Yangsan 
Hospital in Yangsan, Korea.
Statistical analysis
All data are given as mean±standard deviation for continuous 
variables. Median values are also indicated in the cases of AST, 
ALT, TG, and high sensitivity C-reactive protein (hs-CRP), 
which have skewed distributions. Components of MetS and 
other clinical characteristics were compared between subjects 
with and without MetS using an independent-sample Student’s 
t-test and Mann-Whitney U test in variables with a skewed 
distribution. To evaluate the association between apoA-II and 
other variables, including apoA-I and apoB, we performed 
Pearson’s partial correlation coefficients analyses, adjusting for 
age and sex. Because triglycerides and hs-CRP levels had 
skewed distributions, values were log-transformed before sta-
tistical analysis. The total subjects were divided into quartiles 
based on the distribution of apoA-I, apoA-II, and apoB. The 
prevalence of MetS in each quartile was indicated as a percent-
age and compared using the chi-square test. Finally, the odd 
ratios and corresponding 95% confidence intervals for the 
highest quartile of apoA-I, apoA-II, and apoB were calculated 
as an estimate of the relative risk of MetS by logistic regression 
analyses, with the lowest quartile used as the reference catego-
ry. Statistical analyses were performed with an SPSS statistical 
package (SPSS Inc., Chicago, IL, USA). A probability value of 
less than 0.05 was considered significant.
RESULTS
The prevalence of MetS in this study was 26.2%. All values of 
MetS components were significantly higher in subjects with 58
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MetS than in those without MetS. ApoA-I levels were signifi-
cantly lower (128.0±20.3 mg/dL vs. 137.4±18.5 mg/dL; P=
0.001) and apoB levels were significantly higher (101.7±24.2 
mg/dL vs. 88.9±20.4 mg/dL; P<0.001) in the MetS group 
compared with the non-MetS group. ApoA-II levels were low-
er (30.5±4.6 mg/dL vs. 31.2±4.6 mg/dL; P=0.261) in the 
MetS group, but there was no statistical significance (Table 1).
  After adjusting for age and sex, apoA-II levels were more 
positively correlated with apoA-I levels (r=0.587, P<0.001) 
than apoB levels (r=0.166, P=0.009). When the significant 
correlation was limited to a coefficient >0.200, apoB levels 
showed significant positive correlations with diastolic blood 
pressure (r=0.237, P<0.001) and logTG (r=0.386, P<0.001). 
ApoB also showed weak positive correlations with waist cir-
cumference (r=0.180), BMI (r=0.199), and systolic blood 
pressure (r=0.158). ApoA-I levels showed weak negative cor-
relations with waist circumference (r=-0.131), BMI (r=-0.181), 
logTG (r=-0.135), and fasting glucose levels (r=-0.142). ApoA-
II levels showed significant positive correlation with HDL-C 
levels (r=0.438, P<0.001), but its correlation was weaker than 
that of apoA-I levels (r=0.857, P<0.001). ApoB levels showed 
significant negative correlation with HDL-C levels (r=-0.241, 
P<0.001). Among the inflammatory markers, apoA-II levels 
were less negatively correlated with homocysteine and log (hs-
CRP) (r=-0.109, P=0.098, and r=-0.163, P=0.013, respec-
tively) than apoA-I levels (r=-0.177, P=0.006, and r=-0.221, 
Table 1. Clinical characteristics of the study subjects (n=244)
Parameter Total MetS (n=64) Non-MetS (n=180) P value
Age, yr 52.9±8.2 53.1±7.9 52.8±8.4 0.771
BMI, kg/m
2 24.5±2.9 26.4±2.9 23.8±2.6 <0.001
WC, cm 88.2±7.6 93.8±6.5 86.2±7.0 <0.001
SBP, mm Hg 121.2±13.3 128.4±12.3 118.7±12.7 <0.001
DBP, mm Hg 79.4±10.0 85.0±8.9 77.4±9.6 <0.001
FBS, mg/dL 99.9±36.6 116.6±50.9 93.9±27.7 0.001
HbA1c, % 5.8±0.8 6.3±1.2 5.6±0.6 <0.001
ApoA-I, mg/dL 134.9±19.4 128.0±20.3 137.4±18.5 0.001
ApoA-II, mg/dL 31.0±4.6 30.5±4.6 31.2±4.6 0.261
ApoB, mg/dL 92.2±22.2 101.7±24.2 88.9±20.4 <0.001
TC, mg/dL 217.8±38.6 217.5±46.3 217.9±35.6 0.953
TG, mg/dL 130.0±97.4 (102.5) 201.6±118.2 (178.5) 104.5±74.1 (84.5) <0.001
a
HDL-C, mg/dL 53.7±14.0 44.5±11.6 56.9±13.4 <0.001
LDL-C, mg/dL 139.3±34.3 140.3±39.3 139.0±32.5 0.819
AST, IU/L 28.1±13.4 (25) 33.0±20.5 (27) 26.3±9.2 (24.5) 0.035
a
ALT, IU/L 30.0±22.4 (24) 37.9±30.1 (26) 27.2±18.2 (22.5) 0.030
a
Uric acid, mg/dL 5.6±1.5 5.9±1.5 5.5±1.6 0.111
BUN, mg/dL 16.5±4.2 15.7±3.7 16.7±4.3 0.053
Creatinine, mg/dL 1.0±0.2 1.0±0.2 1.0±0.2 0.142
hs-CRP, mg/dL 0.17±0.27 (0.08) 0.27±0.36 (0.15) 0.13±0.22 (0.65) <0.001
a
Homocysteine, umol/L 12.8±5.3 13.2±3.9 12.7±5.6 0.432
Cystatin-C, mg/L 0.80±1.40 0.83±0.15 0.78±0.13 0.027
Data are presented as mean±standard deviation (median) unless otherwise indicated. P value was calculated from independent t-test unless 
otherwise indicated. 
MetS, metabolic syndrome; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBS, 
fasting blood sugar; ApoA-I, apolipoprotein A-I; ApoA-II, apolipoprotein A-II; ApoB, apolipoprotein B; TC, total cholesterol; TG, triglyceride; 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine ami-
notransferase; BUN, blood urea nitrogen; hs-CRP, high sensitivity C-reactive protein. 
aMann-Whitney test.59
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P=0.001, respectively) (Table 2).
  Among the components of MetS, apoA-II levels were sig-
nificantly higher in subjects with hypertriglyceridemia (32.2± 
4.7 mg/dL vs. 30.5±4.4 mg/dL; P=0.013), and significantly 
lower in subjects with low HDL-C levels (27.9±3.1 mg/dL vs. 
31.8±4.5 mg/dL; P<0.001). ApoA-I levels were significantly 
lower in subjects with low HDL-C levels (114.2±11.0 mg/dL 
vs. 140.1±17.5 mg/dL; P<0.001). ApoB levels were signifi-
cantly higher in subjects with hypertriglyceridemia (104.5± 
25.4 mg/dL vs. 87.5±18.8 mg/dL; P<0.001) and high blood 




r P value r P value r P value
ApoA-I - - 0.587  <0.001 -0.144  0.026
ApoA-II 0.587  <0.001 - - 0.166  0.009
ApoB -0.144  0.026 0.166  0.009 - -
WC -0.131  0.044 0.058 0.342 0.180  0.005
BMI -0.181  0.005 0.051 0.406 0.199  0.001
SBP -0.103  0.113 0.007  0.857 0.158  0.014
DBP -0.072  0.284 0.073  0.210 0.237  <0.001
Log (TG) -0.135  0.038 0.109  0.091 0.386  <0.001
HDL-C 0.857  <0.001 0.438  <0.001 -0.241  <0.001
Glucose -0.142  0.029 -0.079  0.229 -0.001 0.992
HbA1c -0.149  0.021 -0.052  0.427 0.129  0.043
Log (hs-CRP) -0.221  0.001 -0.163  0.013 0.128  0.046
Homocysteine -0.177  0.006 -0.109 0.098 0.058 0.368
Cystatin-C -0.248  <0.001 -0.247  <0.001 0.058  0.372
ApoA-I, apolipoprotein A-I; ApoA-II, apolipoprotein A-II; ApoB, apolipoprotein B; WC, waist circumference; BMI, body mass index; SBP, sys-
tolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; hs-CRP, high sensitivity C-
reactive protein.
Table 3. Comparison of mean ApoA-I, ApoA-II, and ApoB levels between subjects with and without individual metabolic com-
ponent disorders
Metabolic disorder
ApoA-I, mg/dL ApoA-II, mg/dL ApoB, mg/dL
Mean±SD P value Mean±SD P value Mean±SD P value
Abdominal obesity (n=121) 133.7±19.1 0.308 31.2±4.6 0.586 94.6±23.5 0.095
Normal (n=123) 136.2±19.7 30.9±4.5 89.9±20.6
Hypertriglyceridemia (n=68) 132.9±20.2 0.326 32.2±4.7 0.013 104.5±25.4 <0.001
Normal (n=176) 135.7±19.1 30.5±4.4 87.5±18.8
Low-HDL (n=48) 114.2±11.0 <0.001 27.9±3.1 <0.001 95.2±21.8 0.290
Normal (n=196) 140.1±17.5 31.8±4.5 91.5±22.2
Hyperglycemia (n=76) 133.7±20.8 0.524 31.1±5.0 0.902 93.7±26.3 0.521
Normal (n=168) 135.5±18.8 30.9±4.4 91.5±20.0
High blood pressure (n=100) 132.8±20.3 0.150 30.9±4.7 0.862 98.5±23.0 <0.001
Normal (n=144) 136.5±18.7 31.1±4.5 87.9±20.5
Data are presented as mean±standard deviation. P value was calculated from independent t-test.
ApoA-I, apolipoprotein A-I; ApoA-II, apolipoprotein A-II; ApoB, apolipoprotein B; SD, standard deviation; HDL, high density lipoprotein.60
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pressure (98.5±23.0 mg/dL vs. 87.9±20.5 mg/dL; P<0.001) 
(Table 3).
  These three markers were divided into quartiles and the 
prevalence of MetS was evaluated. The prevalence of MetS sig-
nificantly decreased with an increase in apoA-I quartile (12.3%, 
4.1%, 4.9%, and 4.9%; P<0.001). Conversely, MetS significant-
ly increased with an increase in apoB quartile (4.9%, 4.1%, 
7.0%, and 10.2%; P=0.007). However, there were no signifi-
cant differences in MetS prevalence according to the increase 
in apoA-II quartile (9.0%, 5.7%, 4.9%, and 6.6%; P=0.279) 
(Fig. 1). 
  In logistic regression analysis after adjusting for age and sex, 
the relative risk of the highest quartile of apoA-I compared 
with the lowest quartile was significantly decreased (odds ratio 
[OR], 0.46; 95% confidence interval [CI], 0.09 to 0.82; P=
0.027), and that of apoB was significantly increased (OR, 3.27; 
95% CI, 1.36 to 7.86; P=0.010). However, there was no signifi-
cant difference in the case of apoA-II (OR, 0.96; 95% CI, 0.95 
to 1.04; P=0.956) (Table 4).
DISCUSSION
In the present study, we tried to evaluate the relationship be-
tween apoA-II and MetS in comparison with apoA-I (a mark-
er for anti-atherogenic properties) and apoB (a marker for pro-
atherogenic properties) in Korean subjects. ApoA-I levels were 
found to be significantly lower in the MetS group and they 
were negatively correlated with components of MetS, such as 
waist circumference, triglyceride levels, and fasting glucose 
levels. ApoA-II levels, however, did not differ significantly be-
tween the MetS group and non-MetS group and showed no 
significant correlations with MetS components, except HDL-
C. Furthermore, apoA-II was less negatively correlated with 
homocysteine and hs-CRP values, which are also known as 
markers with pro-atherogenic potential, than was apoA-I with 
homocysteine and hs-CRP values. With regard to the relation-
ship between homocysteine and apoA-II, Taskinen et al. [17], 
reported that the greater the increase in homocysteine levels 
induced by fenofibrate, the smaller the increases in HDL-C 
and apoA-I levels, but there was a highly significant and posi-
tive relationship between fenofibrate-induced changes in ho-
mocysteine and apoA-II levels. These findings may suggest 
that apoA-II is less anti-atherogenic than apoA-I [18,19]. Ac-
cording to another study [9], apoA-II accounts for about 20% 
of HDL, and mean serum apoA-II concentrations are general-
ly 4 times lower than mean apoA-I levels in normolipidemic 
subjects. So, this may explain our result of apoA-II being posi-
tively correlated with HDL-C levels (r=0.438), while its corre-
lation was also weaker than that of apoA-I levels (r=0.857). 
  In a study by Birjmohun et al. [9], apoA-II levels showed 
positive correlation with triglyceride and HDL-C levels in 
spite of the inverse correlation between triglyceride and HDL-
C levels. The authors explained that this result may be due to 
apoA-II inhibiting lipoprotein lipase and hepatic lipase activi-
ties, resulting in less hydrolysis of triglyceride-rich lipoproteins, 
which leads to increased triglyceride levels. In our study, apoA-
II levels were positively correlated with apoB levels (r=0.166), 
as well as apoA-I levels, and apoA-II levels were significantly 
higher in the hypertriglyceridemic group. These findings also 
appear consistent with a previous study related to the pro-ath-
Table 4. Adjusted ORs (95% CI) for metabolic syndrome in 
the highest quartiles of ApoA-I, Apo A-II, and ApoB com-
pared with the lowest quartiles using logistic regression analy-
ses and adjusted by age and sex
Parameter
Metabolic syndrome
OR (95% CI) P value
ApoA-I 0.46 (0.09-0.82) 0.027
ApoA-II 0.96 (0.95-1.04) 0.956
ApoB 3.27 (1.36-7.86) 0.010
OR, odds ratio; CI, confidence interval; ApoA-I, apolipoprotein A-I; 
ApoA-II, apolipoprotein A-II; ApoB, apolipoprotein B.
Fig. 1. Prevalence of metabolic syndrome according to quar-
tiles of ApoA-I, ApoA-II, and ApoB. Graphic bars are expressed 
as percent. Differences in prevalence among quartiles of each 
lipid marker were analysed using the chi-square test. ApoA-I, 
apolipoprotein A-I; ApoA-II, apolipoprotein A-II; ApoB, apo-
lipoprotein B; 1, 1st quartile; 2, 2nd quartile; 3, 3rd quartile; 4, 
4th quartile. 
aP<0.001; 
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erogenic potentials of apoA-II [10]. 
  Recently, Onat et al. [13] showed that low serum apoA-II 
concentrations appear to predict incident MetS (relative risk, 
3.5) and type 2 diabetes mellitus (relative risk, 4.5) in both sex-
es at an increment of 1 standard deviation, which is consistent 
with previous studies [6-9]; however, increased apoA-II values 
were not associated with prevalent or incident CHD and tend-
ed to be marginally atheroprotective only in males. In our study, 
the prevalence of Mets decreased as the quartiles of apoA-I in-
creased, and increased with increasing quartiles of apoB, but 
there were no significant differences in MetS percentage be-
tween quartiles of apoA-II. Moreover, the relative risk of the 
highest quartile of apoA-II compared with the lowest quartile 
was not significantly different in logistic regression analysis af-
ter adjusting for age and sex. Birjmohun et al. [9] demonstrat-
ed that apoA-II levels are associated with a decreased risk of 
future CAD in apparently healthy people in a nested case-con-
trol study in the prospective EPIC-Norfolk cohort in the Unit-
ed Kingdom, but the authors commented that application of 
these results to non-white populations must be done with cau-
tion. So, given the results of Onat et al. [13] and our study, the 
possible role of apoA-II in cardiometabolic risk in Asian pop-
ulations may be marginally atheroprotective or inconclusive. 
  It is widely known that HDL-C reduces cardiometabolic 
risk by enhancing the transfer of peripheral free cholesterol to 
the liver through the process called ‘reverse cholesterol trans-
port.’ Some studies have reported that HDL containing apoA-I 
might be more effective in capturing cell-derived cholesterol 
for cholesterol efflux, the first step of reverse cholesterol trans-
port, than HDL containing both apoA-I and apoA-II [20,21]. 
Furthermore, the effects of apoA-II on HDL metabolism are 
more complex and it may have both potential deleterious ef-
fects and beneficial effects [22]. The pro-atherogenic proper-
ties of apoA-II may inhibit lecithin-cholesterol acyltransferase 
[23,24], and inhibit hepatic cholesteryl uptake from HDL prob-
ably through the class B type 1 scavenger receptor dependent 
pathway [25,26]. The anti-atherogenic properties of apoA-II 
may inhibit cholesteryl ester transfer protein activity [27] and 
increase hepatic lipase activity [28]. Thus, our findings provide 
further evidence of the complex relationship between apoA-II 
and cardiovascular risk.
  Our study has several limitations. First, it was performed 
using a cross-sectional design and did not control for potential 
biases from diet, physical activity, smoking and drinking his-
tory, and drug medication status (except for anti-lipid agents). 
Second, the total number of enrolled subjects was relatively 
small. Thus, a large-scale, prospective study will be needed to 
elucidate the exact role of apoA-II in cardiovascular disease.
  In summary, apoA-II levels did not show any association 
with MetS in this study of Korean adults. However, apoA-II 
may have both anti-atherogenic and pro-atherogenic proper-
ties that may be caused by the diverse activities of apoA-II in 
association with cardiometabolic risk. 
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